Stockscreener 앱 받기
13.78
3.28%
-0.23
전일 마감가:
$14.01
열려 있는:
$14.13
하루 거래량:
48,818
Relative Volume:
0.18
시가총액:
$187.70M
수익:
-
순이익/손실:
$-104.29M
주가수익비율:
-2.2841
EPS:
-6.0329
순현금흐름:
$-81.45M
1주 성능:
+10.52%
1개월 성능:
+12.17%
6개월 성능:
+125.68%
1년 성능:
+65.14%
1일 변동 폭
$13.50
$14.24
1주일 범위
$11.55
$14.40
52주 변동 폭
$5.062
$15.77
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
13.78 | 190.84M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
448.15 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.82 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.88 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.92 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.14 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-15 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2026-03-24 | 개시 | Guggenheim | Buy |
| 2025-11-07 | 개시 | Roth Capital | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
IMUX - Finviz
Immunic Inc Stock (US45256V1061): Biotech share in focus after recent volatility - AD HOC NEWS
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic to showcase IMU-856 research at June conferences - Proactive financial news
Immunic to Participate in Investor, Industry and Scientific Conferences in June - AD HOC NEWS
IMUX Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Pipeline ProgressEarnings Cycle Outlook - newsline.com
IMUX Stock Price, Quote & Chart - ChartMill
Immunic stock (US45256V1061): Pipeline updates keep investor focus on late-stage catalysts - AD HOC NEWS
Immunic Inc. (IMUX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Sharp SelloffEarnings Sentiment Score - newsline.com
Cost of goods sold of Immunic, Inc. – DUS:10V - TradingView
IMUX Q1 2026 Earnings: EPS Misses Estimates, Stock Dips 3.24%Final Results - newsline.com
IMMUNIC (IMUX) CEO Erik Lundgren files initial Form 3 insider report - Stock Titan
MS expert takes the helm - European Biotechnology Magazine
Immunic (IMUX) proxy details 6M-share plan increase and 22.2% dilution - Stock Titan
Stifel Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Immunic to Present Phase 2 CALLIPER Trial Data on Vidofludimus Calcium Impact on Neurofilament Light Chain in Progressive MS at CMSC 2026 - geneonline.com
Immunic Presents Promising Phase 2 CALLIPER Data for Vidofludimus Calcium in Progressive Multiple Sclerosis, Highlighting Safety, Efficacy, and Novel Disability Assessment Methods 1 - Minichart
Market movers: Dell, Immunic, Dollar Tree, Synopsys, Best Buy, Giyani Metals... - Proactive financial news
Immunic presents new vidofludimus calcium data at multiple sclerosis conference - Yahoo! Finance Canada
Immunic Appoints New CEO to Lead MS Strategy - The Globe and Mail
Immunic Presents Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium At Cmsc Annual Meeting - marketscreener.com
Immunic to Present Additional Phase 2 CALLIPER Data Showing Favorable Safety and Disability Signals for Vidofludimus Calcium - TradingView
New CALLIPER MS data for vidofludimus calcium at CMSC 2026 (IMUX) - Stock Titan
Progressive MS drug shows similar safety to placebo, no mood worsening 120 weeks - Stock Titan
Immunic appoints Erik Lundgren as new CEO By Investing.com - Investing.com Australia
Immunic names Erik Lundgren as CEO; Daniel Vitt steps down - MSN
Immunic Therapeutics Welcomes New CEO Erik Lundgren - Contract Pharma
Small cap wrap: Standard Uranium, Blockmate Ventures, Abacus Global, Immunic, Virtuix… - Proactive financial news
Immunic (IMUX) Appoints Erik Lundgren as New CEO Effective May 2 - GuruFocus
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial By Investing.com - Investing.com India
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial - Investing.com Australia
Immunic, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials - Yahoo Finance
Immunic lures former Roche exec Erik Lundgren to be its CEO - The Pharma Letter
Immunic Names Erik Lundgren Chief Executive - Moomoo
Erik Lundgren becomes Immunic (Nasdaq: IMUX) CEO with milestone-tied pay - Stock Titan
Immunic appoints Erik Lundgren as new CEO - Investing.com UK
Press Release: Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - Moomoo
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO - Yahoo Finance
William Blair Maintains Immunic(IMUX.US) With Buy Rating - Moomoo
Immunic (IMUX) Surges 6% as Biotech Shares Rebound – Key Levels to WatchInitial Balance - newsline.com
Wolfe Research initiated coverage on Immunic - Quantisnow
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.61%
자본화:
|
볼륨(24시간):